Literature DB >> 9332391

Isolation and nucleotide sequence of human liver glycogen debranching enzyme mRNA: identification of multiple tissue-specific isoforms.

Y Bao1, B Z Yang, T L Dawson, Y T Chen.   

Abstract

Glycogen storage disease type III (GSD-III) is caused by a deficiency of glycogen debranching enzyme (AGL) activity. Patients are found to have deficient AGL activity in both muscle and liver, and also enzyme deficiency in the liver, but not in muscle. To determine the molecular basis of enzymatic variability in GSD-III and to elucidate the mechanism for control of tissue-specific expression of AGL, we previously cloned and sequenced the human muscle AGL cDNA. Here we report the isolation and nucleotide sequence of liver AGL cDNA and the tissue distribution of the isoform mRNAs. The predominant form of human liver AGL cDNA (isoform 1) contained 400 bp of 5' untranslated region, 4596 bp of coding region, and 2371 bp of 3' untranslated region. The liver AGL mRNA sequence was identical to the previously published muscle sequence (isoform 5) for most of the length, except for the 5' end, in which the liver sequence diverged completely from the muscle sequence. The divergence began with the transcription start point and extended 82 nucleotides downstream from the translation initiation codon. Six isoforms of AGL mRNA were identified and sequenced from liver and muscle. These isoforms differed only at the 5' end. Tissue distribution studies showed that liver, kidney and lymphoblastoid cells expressed predominantly isoform 1; whereas muscle and heart expressed not only isoform 1, but also muscle-specific isoform mRNAs (isoforms 2, 3 and 4). Defining tissue-specific AGL isoform mRNAs is an important step toward understanding the molecular basis of enzymatic variability in GSD-III.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9332391     DOI: 10.1016/s0378-1119(97)00291-6

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  14 in total

1.  Novel mutations in two Japanese cases of glycogen storage disease type IIIa and a review of the literature of the molecular basis of glycogen storage disease type III.

Authors:  T Fukuda; H Sugie; M Ito
Journal:  J Inherit Metab Dis       Date:  2000-03       Impact factor: 4.982

2.  Molecular analysis of the AGL gene: heterogeneity of mutations in patients with glycogen storage disease type III from Germany, Canada, Afghanistan, Iran, and Turkey.

Authors:  Yoriko Endo; Asako Horinishi; Matthias Vorgerd; Yoshiko Aoyama; Tetsu Ebara; Toshio Murase; Masato Odawara; Teodor Podskarbi; Yoon S Shin; Minoru Okubo
Journal:  J Hum Genet       Date:  2006-09-19       Impact factor: 3.172

3.  Novel exon 11 skipping mutation in a patient with glycogen storage disease type IIId.

Authors:  H Sugie; T Fukuda; M Ito; Y Sugie; T Kojoh; I Nonaka
Journal:  J Inherit Metab Dis       Date:  2001-10       Impact factor: 4.982

Review 4.  Specific features of glycogen metabolism in the liver.

Authors:  M Bollen; S Keppens; W Stalmans
Journal:  Biochem J       Date:  1998-11-15       Impact factor: 3.857

5.  Mutation Analysis in Glycogen Storage Disease Type III Patients in the Netherlands: Novel Genotype-Phenotype Relationships and Five Novel Mutations in the AGL Gene.

Authors:  Christiaan P Sentner; Yvonne J Vos; Klary N Niezen-Koning; Bart Mol; G Peter A Smit
Journal:  JIMD Rep       Date:  2012-03-16

6.  Molecular characterization of Egyptian patients with glycogen storage disease type IIIa.

Authors:  Yoriko Endo; Ekram Fateen; Yoshiko Aoyama; Asako Horinishi; Tetsu Ebara; Toshio Murase; Yoon S Shin; Minoru Okubo
Journal:  J Hum Genet       Date:  2005-09-28       Impact factor: 3.172

7.  Comparative analysis of the glg operons of Pectobacterium chrysanthemi PY35 and other prokaryotes.

Authors:  Kye Man Cho; Woo Jin Lim; Renukaradhya K Math; Shah Md Asraful Islam; Sun Joo Hong; Hoon Kim; Han Dae Yun
Journal:  J Mol Evol       Date:  2008-07-02       Impact factor: 2.395

8.  Reversal of glycogen storage disease type IIIa-related cardiomyopathy with modification of diet.

Authors:  A I Dagli; R T Zori; H McCune; T Ivsic; M K Maisenbacher; D A Weinstein
Journal:  J Inherit Metab Dis       Date:  2009-03-30       Impact factor: 4.982

Review 9.  Glycogen storage diseases: new perspectives.

Authors:  Hasan Ozen
Journal:  World J Gastroenterol       Date:  2007-05-14       Impact factor: 5.742

10.  Reduction in bone mineral density in glycogenosis type III may be due to a mixed muscle and bone deficit.

Authors:  H R Mundy; J E Williams; P J Lee; M S Fewtrell
Journal:  J Inherit Metab Dis       Date:  2008-04-04       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.